- Home
- TCBP vs BPTH Comparison
TCBP vs BPTH Comparison
Compare TCBP & BPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBP
- BPTH
- Stock Information
- Founded
- TCBP 2013
- BPTH 2007
- Country
- TCBP United Kingdom
- BPTH United States
- Employees
- TCBP N/A
- BPTH N/A
- Industry
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- BPTH Biotechnology: Pharmaceutical Preparations
- Sector
- TCBP Health Care
- BPTH Health Care
- Exchange
- TCBP Nasdaq
- BPTH Nasdaq
- Market Cap
- TCBP 3.0M
- BPTH 2.8M
- IPO Year
- TCBP 2022
- BPTH N/A
- Fundamental
- Price
- TCBP $0.65
- BPTH $0.67
- Analyst Decision
- TCBP Strong Buy
- BPTH Strong Buy
- Analyst Count
- TCBP 1
- BPTH 2
- Target Price
- TCBP $3.00
- BPTH $30.00
- AVG Volume (30 Days)
- TCBP 1.8M
- BPTH 107.0K
- Earning Date
- TCBP 02-09-2025
- BPTH 11-15-2024
- Dividend Yield
- TCBP N/A
- BPTH N/A
- EPS Growth
- TCBP N/A
- BPTH N/A
- EPS
- TCBP N/A
- BPTH N/A
- Revenue
- TCBP N/A
- BPTH N/A
- Revenue This Year
- TCBP N/A
- BPTH N/A
- Revenue Next Year
- TCBP N/A
- BPTH N/A
- P/E Ratio
- TCBP N/A
- BPTH N/A
- Revenue Growth
- TCBP N/A
- BPTH N/A
- 52 Week Low
- TCBP $0.44
- BPTH $0.59
- 52 Week High
- TCBP $41.50
- BPTH $12.00
- Technical
- Relative Strength Index (RSI)
- TCBP 36.84
- BPTH 39.07
- Support Level
- TCBP $0.45
- BPTH $0.64
- Resistance Level
- TCBP $0.70
- BPTH $0.90
- Average True Range (ATR)
- TCBP 0.08
- BPTH 0.10
- MACD
- TCBP 0.10
- BPTH 0.01
- Stochastic Oscillator
- TCBP 55.58
- BPTH 25.48
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.